The IPO Buzz: AgomAb Therapeutics (AGMB) Prices IPO at $16 & Joins ‘The Mid-Point Club’
Mid-point pricing is the trend. AgomAb Therapeutics NV (AGMB), a Belgian biotech backed by Pfizer, priced its IPO at $16.00 – the mid-point of its range – last night. That put AgomAb Therapeutics right in step with SpyGlass Pharma (SGP) and Jennifer Garner’s Once Upon a Farm (OFRM) – both IPOs also priced at the mid-point […]
February 6, 2026 Read More